logo
Plus   Neg
Share
Email

Sanofi Reports Phase 3 Topline Trial Results Of Iniparib & Otamixaban

Sanofi (SNYNF,SNY) announced topline results of two Phase 3 studies of its investigational compounds iniparib and otamixaban respectively.

The randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer failed to meet its primary endpoint. During the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone.

Topline results of the completed Phase 3 trial of the investigational anticoagulant otamixaban demonstrated that the study failed to meet its primary endpoint of superiority over current therapy. In the TAO study, due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation acute coronary syndrome patients planned for early invasive strategy. The primary endpoint of the Phase 3 TAO trial was the reduction of all-cause mortality or new heart attacks.

As a result, the company would terminate the investigational program with otamixaban, an injectable factor Xa inhibitor.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Facing criticism from the government's top ethics watchdog, Commerce Secretary Wilbur Ross revealed Thursday he will sell all of his remaining stock holdings. A well-known investor prior to joining President Donald Trump's administration, Ross acknowledged making inadvertent errors in completing the divestitures required by his ethics agreement. Worldwide personal-computer shipments grew for the first time in six years during the second quarter of 2018, according to preliminary data from two market research firms. Gartner Inc. said that worldwide PC shipments increased 1.4 percent year-over-year to 62.1 million units in the second quarter of 2018, marking the first quarter of growth since the first quarter of 2012. The Centers for Disease Control and Prevention or CDC has recommended people to not eat any Kellogg Co.'s Honey Smacks cereal as it has been linked to a multistate outbreak of salmonella infections. According to the CDC, 100 people in 33 states have been infected with the outbreak strain. While 30 people have been hospitalized, no deaths have been reported.
Follow RTT